Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

11/14/24 12:55:40 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MIRM alert in real time by email

SC 13G/A 1 Mirum093024.txt JANUS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 1* Name of Issuer: Mirum Pharmaceuticals, Inc. Title of Class of Securities: Common Stock CUSIP Number: 604749101 Date of Event Which Requires Filing of this Statement: 9/30/2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed. [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No.: 604749101 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Janus Henderson Group plc EIN #00-0000000 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP a. ___ b. ___ 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Jersey, Channel Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5. SOLE VOTING POWER 0** 6. SHARED VOTING POWER 4,480,284** 7. SOLE DISPOSITIVE POWER 0** 8. SHARED DISPOSITIVE POWER 4,480,284** 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,480,284** 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES Not applicable 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.4%** 12. TYPE OF REPORTING PERSON IA, HC ** See Item 4 of this filing Item 1. (a). Name of Issuer: Mirum Pharmaceuticals, Inc. ("Mirum") (b). Address of Issuer's Principal Executive Offices: 989 EAST HILLSDALE BOULEVARD, SUITE 300 FOSTER CITY, CA, 94404 Item 2. (a).-(c). Name, Principal Business Address, and Citizenship of Persons Filing: (1) Janus Henderson Group plc 201 Bishopsgate EC2M 3AE, United Kingdom Citizenship: Jersey, Channel Islands (d). Title of Class of Securities: Common Stock (e). CUSIP Number: 604749101 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) and the person filing, Janus Henderson Group plc ("Janus Henderson") is a parent holding company/control person in accordance with Section 240.13d-1(b)(ii)(G). See Item 4 for additional information. Item 4. Ownership The information in items 1 and 5 through 11 on the cover page(s) on Schedule 13G is hereby incorporated by reference. Janus Henderson has a 100% ownership stake in Janus Henderson Investors U.S. LLC ("JHIUS"), Janus Henderson Investors UK Limited ("JHIUKL") and Janus Henderson Investors Australia Institutional Funds Management Limited ("JHIAIFML"), (each an "Asset Manager" and collectively as the "Asset Managers"). Due to the above ownership structure, holdings for the Asset Managers are aggregated for purposes of this filing. Each Asset Manager is an investment adviser registered or authorized in its relevant jurisdiction and each furnishing investment advice to various fund, individual and/or institutional clients (collectively referred to herein as "Managed Portfolios"). As a result of its role as investment adviser or sub-adviser to the Managed Portfolios, JHIUS may be deemed to be the beneficial owner of 4,458,649 shares or 9.3% of the shares outstanding of Mirum Common Stock held by such Managed Portfolios. However, JHIUS does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaims any ownership associated with such rights. Item 5. Ownership of Five Percent or Less of a Class Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person The Managed Portfolios, set forth in Item 4 above, have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts. The interest of any one such Managed Portfolio does not exceed 5% of the class of securities. These shares were acquired in the ordinary course of business, and not with the purpose of changing or influencing control of the Issuer. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios. Item 8. Identification and Classification of Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. JANUS HENDERSON GROUP PLC By /s/ Kristin Mariani Kristin Mariani, Head of North America Compliance, CCO Date 11/14/2024 Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his or her authorized representative. If the statement is signed on behalf of a person by his or her authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement (see Exhibit A), provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his or her signature. EXHIBIT A POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

Get the next $MIRM alert in real time by email

Recent Analyst Ratings for

$MIRM

Date	Price Target	Rating	Analyst
6/2/2026	$145.00	Buy	Citigroup
5/19/2026	$145.00	Outperform	Wolfe Research
2/18/2026	$130.00	Outperform	RBC Capital Mkts
9/24/2025	$95.00	Buy	TD Cowen
8/11/2025	$89.00	Buy	Stifel
5/19/2025	$73.00	Buy	H.C. Wainwright
4/17/2024	$48.00	Buy	Stifel
12/18/2023	$60.00 → $58.00	Buy	H.C. Wainwright

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

11/14/24 12:55:40 PM ET

$MIRM

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MIRM alert in real time by email

Recent Analyst Ratings for

$MIRM

Date	Price Target	Rating	Analyst
6/2/2026	$145.00	Buy	Citigroup
5/19/2026	$145.00	Outperform	Wolfe Research
2/18/2026	$130.00	Outperform	RBC Capital Mkts
9/24/2025	$95.00	Buy	TD Cowen
8/11/2025	$89.00	Buy	Stifel
5/19/2025	$73.00	Buy	H.C. Wainwright
4/17/2024	$48.00	Buy	Stifel
12/18/2023	$60.00 → $58.00	Buy	H.C. Wainwright

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$MIRM

Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$MIRM

$MIRM
Analyst Ratings

Citigroup initiated coverage on Mirum Pharmaceuticals with a new price target

Wolfe Research initiated coverage on Mirum Pharmaceuticals with a new price target

RBC Capital Mkts initiated coverage on Mirum Pharmaceuticals with a new price target

$MIRM
Press Releases

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$MIRM
SEC Filings

SEC Form 144 filed by Mirum Pharmaceuticals Inc.

SEC Form 144 filed by Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

$MIRM
Insider Purchases

Director Heron Patrick J acquired 159,277 shares and bought $8,999,984 worth of shares (131,425 units at $68.48) (SEC Form 4)

Director Heron Patrick J bought $24,214 worth of shares (549 units at $44.11) (SEC Form 4)

Director Heron Patrick J bought $99,518 worth of shares (2,298 units at $43.31) (SEC Form 4)

$MIRM
Insider Trading

Director Cardon Lon converted options into 3,977 shares, increasing direct ownership by 70% to 9,680 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER Peetz Christopher exercised 30,000 shares at a strike of $2.94 and sold $2,875,103 worth of shares (30,000 units at $95.84) as part of a pre-agreed trading plan (SEC Form 4)

Director Walbert Timothy P converted options into 3,977 shares, increasing direct ownership by 70% to 9,680 units (SEC Form 4)

$MIRM
FDA approvals

February 21, 2025 - FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease

$MIRM
Financials

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026

$MIRM
Large Ownership Changes